"A preemptive strike against cancer" (News: Analysis & Commentary, June 7) and the accompanying table referred to Merck & Co.'s (MRK) Proscar (finasteride) as an anti-baldness drug. Proscar, approved for the treatment of enlarged prostates, was able in a large trial to reduce risk of prostate cancer by 25%. Procepia (also finasteride) is used to treat baldness.
"From Pain Therapeutics (PTIE), a better painkiller?" (Inside Wall Street, June 14) should have said it expects to begin Phase III clinical trials by yearend (not file with the Food & Drug Administration for approval).